Locations:
Search IconSearch
September 15, 2020/Cancer

How COVID-19 Changed Breast Cancer Care

Managing the pandemic's impact on cancer patients

AA-breast-cancer_650x450

The global pandemic has impacted every aspect of patient care with temporary changes that can have lasting impact. Breast cancer care is no exception, according to Chirag Shah, MD, Director of Clinical Research and Breast Radiation in the Department of Radiation Oncology at Cleveland Clinic Cancer Center.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The main issue in the beginning of the pandemic was ensuring that we continued to provide timely access to care,” he says. “Now that COVID-19 has been with us for a while, we are figuring out the best ways to manage timely access while addressing some of the downstream effects of early changes to care.”

Delays in the U.S.

According to 600 responses (83% from the United States and 42% in active treatment) to an online survey conducted by breastcancer.org, about 70% of patients experienced treatment delays in the period prior to June 7. Routine clinical visits (32%), surveillance imaging (14%), routine mammograms (11%), reconstruction (10%), hormonal therapy (5%), mastectomy (5%), radiation therapy (5%) and chemotherapy (4%) were all delayed for some patients. About 30% of these delays were reported as self-chosen, and about 80% of patients reported anxiety that the pandemic would impact their cancer care. More than half of patients used telemedicine.

“It was a delicate balance of COVID-19 risks versus optimizing cancer treatment and outcomes. Many of our patients are immunocompromised or have comorbidities that make COVID-19 potentially more dangerous,” says Dr. Shah. “If we could identify a similarly effective treatment alternative shortened treatment duration, we considered that route.”

“For hormone receptor-positive patients, we often recommended neoadjuvant endocrine therapy for patients who otherwise might have gone directly to surgery in order to avoid potential exposures to COVID-19 in the spring,” says Megan Kruse, MD, medical oncologist and breast specialist at Cleveland Clinic Cancer Center. “Once we determined that the risk to be in the hospital was acceptable, the surgeries resumed as prior to the pandemic.”

Advertisement

From March to now

While many routine visits were shifted to virtual platforms early in the pandemic, new safety measures and procedures have allowed patient visits at Cleveland Clinic Cancer Center to return nearly to pre-pandemic volumes. Patients are screened upon arrival for symptoms and fever and patients and caregivers are masked. Mammograms, screening and diagnostic care are back on track, while multidisciplinary clinics never slowed and continue to be a critical part of Cleveland Clinic Cancer Center care

“Many more patients are opting for in-person visits and often voice that the environment here feels safe to them,” says Dr. Kruse.

Lasting impacts

As the pandemic lingers, physicians across all specialties are expressing concern about its long-term impact on patient care. “Patients are understandably concerned to enter a healthcare setting, and so if someone feels a lump in their breast, they might say ‘Well, it can wait a couple more months,’” says Dr. Shah. “And in some cases, that can mean the difference between an early stage cancer and a more advanced cancer which may alter the rates of treatment success and the treatment required. We are encouraging any patient who has symptoms to see us right away and letting them know we have implemented many safeguards for their protection.”

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad